Events
Case Conversation: COVID-19 Vaccination and ITP
This is a recorded version of the webinar on Case Conversation: COVID-19 Vaccination and ITP that was presented live on February 28th, 2023. Please scroll all the way down this page to view the archived webinar.
Webinar Date: 2/28/2023
Estimated Time to complete: 1 hour
Format: Archived Webinar
Target Audience: Ob/Gyn providers, pediatric/adolescent gynecologists, hematologists, nurse practitioners, and other healthcare professionals
Program Description:
The development of vaccines to contain the coronavirus disease 2019 (COVID-19) pandemic led to vital dissemination and inoculation. With the rapid distribution and use of the SARS-CoV-2 vaccine came many health concerns. Potential cases of de novo immune thrombocytopenia (ITP) induced or exacerbated by the vaccine were explored by using the Vaccine Adverse Events Reporting System (VAERS). Both healthcare providers and patients had growing concern by the impact of the vaccine and its potential to lead to critical bleeding.
Dr. Hanny Al-Samkari and Dr. James Bussel presented the publication, SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Dr. Al-Samkari will also provides recent evidence related to COVID-19 vaccination and ITP, and evidence related to ITP treatment in adolescent females and women.
Learning Objectives:
- Discuss the data pertaining to risk of de novo ITP following COVID-19 vaccination
- Discuss the data pertaining to risk of an acute exacerbation of pre-existing ITP following COVID-19 vaccination
- Describe the treatment and natural history of post-COVID-19 vaccine ITP and the risk of recurrent ITP exacerbation following subsequent COVID-19 vaccines in patients with exacerbation after a prior COVID-19 vaccine
Faculty
James Bussel, MD
Professor Emeritus, Weill Cornell Medicine
Departments of Pediatrics, Medicine and OB-GYN
Hanny Al-Samkari, MD
Assistant Professor, Medicine, Harvard Medical School
Assistant In Medicine, Division of Hematology Oncology, Massachusetts General Hospital
Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence, Medicine, Massachusetts General Hospital
The production, accreditation and archiving of this program were made possible through a sponsorship from Sobi.
